Search results
In June 2012, the FDA approved a combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, prevents disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.
In 2010, The Meningitis Vaccine Project developed an affordable group A conjugate vaccine (MenAfriVac). More than 250 million people have been vaccinated across the meningitis belt and Meningitis A appears to have been controlled in immunised regions.
30 maj 2012 · The prevention of group B meningococcal disease has remained a challenge throughout this period. This review charts the history of the development of meningococcal vaccines and the importance of serological correlates of protection in their evaluation.
Over the past five years, there has been renewed interest in vaccine prevention of meningococcal meningitis mainly through the development of two new vaccination programmes, namely (i) the 4CMenB vaccine to cover meningococcal serogroupB strains 1 and (ii), the introduction of the MenACWY vaccination, in adolescents and the university population 2.
Based on a wide range of historical sources, including published scientific literature and archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the development of the meningococcal A vaccine between 1969 and 1973.
22 kwi 2010 · In the 1960s, the first successful vaccines were developed against groups A and C and were based on capsular polysaccharide. 12 Subsequently, polysaccharide vaccines were introduced against...
7 kwi 2021 · This article examines current and future efforts to control meningitis through vaccination. Keywords: Haemophilus influenzae; Hib; conjugate vaccine; group B streptococcus; meningitis; meningococcus; pneumococcus.
